Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Ambu A/S Class B (AMBFF)
OTHER OTC:AMBFF
Holding AMBFF?
Track your performance easily
Earnings Data
Report Date
Jan 30, 2025TBA Not Confirmed
Period Ending
2025 (Q1)Consensus EPS Forecast
$0.06Last Year’s EPS
$0.05Same Quarter Last Year
Based on 0 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Nov 04, 2024
|% Change Since: 6.19%
|Next Earnings Date:Jan 30, 2025
Earnings Call Sentiment|Neutral
The earnings call presented strong growth in revenue and strategic advancements, particularly in the Endoscopy segment. However, challenges in the GI segment and potential contract losses in Anaesthesia & Patient Monitoring were noted.Company Guidance
During the Ambu Q4 2024 earnings call, detailed guidance was provided for the upcoming fiscal year. The company anticipates an organic revenue growth of 10% to 13%, driven primarily by a projected growth of over 15% in the Endoscopy Solutions segment. This growth is expected to be fueled by existing products and new product launches, such as the ureteroscope and the videolaryngoscope. The Anaesthesia & Patient Monitoring segment is forecasted to achieve mid-single-digit growth, aided by the lingering effects of recent price increases. The EBIT margin is guided to be between 12% and 14%, reflecting an ongoing focus on both gross margin improvement and operational leverage. Ambu also aims to maintain a robust free cash flow of over DKK 500 million, notwithstanding increased capital expenditures to support R&D and production enhancements.Strong Revenue Growth
Q4 revenue grew 10.6%, with 13.8% growth for the full year, driven by a 19.7% increase in Endoscopy.
Endoscopy Segment Success
Endoscopy Solutions saw growth of 14.5% in Q4 and 19.7% for the full year, driven by aScope 5.
Anaesthesia & Patient Monitoring Growth
Anaesthesia & Patient Monitoring grew 6.1% for the full year, with price increases contributing to growth.
Sustainability Milestone
Achieved EcoVadis 'Committed badge' and completed conversion to bioplastic handles for endoscopes.
Cash Flow and Dividend Announcement
Free cash flow of DKK 524 million for the year, with a proposed dividend distribution of DKK 102 million.
---
AMBFF Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
AMBFF Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Nov 04, 2024 | $18.74 | $18.88 | +0.75% |
| Aug 30, 2024 | $22.40 | $19.43 | -13.26% |
| May 14, 2024 | $17.24 | $17.04 | -1.16% |
| Jan 30, 2024 | $16.06 | $17.18 | +6.97% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Ambu A/S Class B (AMBFF) report earnings?
Ambu A/S Class B (AMBFF) is schdueled to report earning on Jan 30, 2025, TBA Not Confirmed.
What is Ambu A/S Class B (AMBFF) earnings time?
Ambu A/S Class B (AMBFF) earnings time is at Jan 30, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is AMBFF EPS forecast?
AMBFF EPS forecast for the fiscal quarter 2025 (Q1) is $0.06.
---